Filtered By:
Specialty: Epidemiology
Cancer: Prostate Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1459 results found since Jan 2013.
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
CONCLUSION: Relugolix suppressed testosterone and was generally well tolerated when given with concomitant CV agents.TRIAL REGISTRATION: Clinical Trial ID NCT03085095.PRIOR PRESENTATION: Data presented at 15th Annual Genitourinary Cancers Symposium; February 17-19, 2022, San Francisco, CA, USA [Abstract 101, Poster board E11]. The published abstract from this presentation can be found at https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.101 .PMID:37713020 | DOI:10.1007/s12325-023-02634-7
Source: Adv Data - September 15, 2023 Category: Epidemiology Authors: Neal D Shore Bryan A Mehlhaff Michael S Cookson Daniel R Saltzstein Ronald Tutrone Bruce Brown Sophia Lu Mark Fallick Sarah Hanson Fred Saad Source Type: research
Selecting the optimal radiation modality in prostate cancer
Clin Adv Hematol Oncol. 2023 Sep;21(9):494-501.ABSTRACTThere are numerous radiation modalities for the definitive treatment of localized prostate cancer. Classic clinical trials have established the basic tenets of treatment approaches, and emerging data have generated new potential avenues of treatment that optimize the therapeutic ratio by increasing prostate cancer tumor control while minimizing treatment-related toxicity. In the definitive setting, the selection of the optimal radiation therapy approach depends largely on the appropriate up-front risk stratification of men with prostate cancer, with greater intensifica...
Source: Adv Data - August 30, 2023 Category: Epidemiology Authors: Luca F Valle Amar U Kishan Antonio Franco Ting Martin Ma John Nikitas Matthew Farrell Albert J Chang Nicholas G Nickols Michael L Steinberg Source Type: research
Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
Ther Adv Urol. 2023 Jun 15;15:17562872231182219. doi: 10.1177/17562872231182219. eCollection 2023 Jan-Dec.ABSTRACTProstate cancer is the most common cancer among men and the second leading cause of cancer-related deaths in men in the United States. The treatment paradigm for prostate cancer has evolved with the emergence of a variety of novel therapies which have improved survival; however, treatment-related toxicities are abundant and durable responses remain rare. Immune checkpoint inhibitors have shown modest activity in a small subset of patients with prostate cancer and have not had an impact on most men with advanced...
Source: Adv Data - June 26, 2023 Category: Epidemiology Authors: Kevin K Zarrabi Vivek Narayan Patrick J Mille Matthew R Zibelman Benjamin Miron Babar Bashir William Kevin Kelly Source Type: research
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review
Ther Adv Med Oncol. 2023 Jun 6;15:17588359231177018. doi: 10.1177/17588359231177018. eCollection 2023.ABSTRACTReported here is a case of rapidly progressive metastatic castration-resistant prostate cancer treated with [177Lu]Lu-PSMA-617 in the setting of severe renal impairment and impending ureteric obstruction. PSMA is expressed on renal tubular cells, raising the possibility of radiation-induced nephrotoxicity, and this level of renal impairment would typically exclude the patient from [177Lu]Lu-PSMA-617 therapy. Multidisciplinary input, individualized dosimetry, and patient-specific dose reduction were used to ensure t...
Source: Adv Data - June 16, 2023 Category: Epidemiology Authors: Duncan E K Sutherland Raghava Kashyap Price Jackson James P Buteau Declan G Murphy Brian Kelly Lavinia Spain Shahneen Sandhu Arun A Azad Elizabeth Medhurst Grace Kong Michael S Hofman Source Type: research
Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer
Ther Adv Med Oncol. 2023 Jun 6;15:17588359231179309. doi: 10.1177/17588359231179309. eCollection 2023.ABSTRACT[177Lu]Lu-PSMA has recently been approved for use in the post-taxane, post-novel hormonal-agent setting in patients with metastatic castration-resistant prostate cancer. As a beta-emitting radioligand targeting prostate-specific membrane antigen (PSMA), it delivers radiation to cells expressing PSMA on their surface. In pivotal clinical trials, patients were selected for this treatment based on positron emission tomography (PET)/CT imaging, requiring PSMA-avid disease with no evidence of discordant disease on 2-[18...
Source: Adv Data - June 16, 2023 Category: Epidemiology Authors: Louise Kostos James P Buteau Michael S Hofman Arun A Azad Source Type: research
Cheese consumption and multiple health outcomes: an umbrella review and updated meta-analysis of prospective studies
Adv Nutr. 2023 Jun 14:S2161-8313(23)01328-5. doi: 10.1016/j.advnut.2023.06.007. Online ahead of print.ABSTRACTThis umbrella review aims to provide a systematic and comprehensive overview of current evidence from prospective studies on the diverse health effects of cheese consumption. We searched PubMed, Embase, and Cochrane Library to identify meta-analyses/pooled analyses of prospective studies examining the associations between cheese consumption and major health outcomes from inception to August 31, 2022. We reanalyzed and updated previous meta-analyses and performed de novo meta-analyses with recently published prospec...
Source: Adv Data - June 16, 2023 Category: Epidemiology Authors: Mingjie Zhang Xiaocong Dong Zihui Huang Xue Li Yue Zhao Yingyao Wang Huilian Zhu Aiping Fang Edward L Giovannucci Source Type: research
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review
Ther Adv Med Oncol. 2023 Jun 6;15:17588359231177018. doi: 10.1177/17588359231177018. eCollection 2023.ABSTRACTReported here is a case of rapidly progressive metastatic castration-resistant prostate cancer treated with [177Lu]Lu-PSMA-617 in the setting of severe renal impairment and impending ureteric obstruction. PSMA is expressed on renal tubular cells, raising the possibility of radiation-induced nephrotoxicity, and this level of renal impairment would typically exclude the patient from [177Lu]Lu-PSMA-617 therapy. Multidisciplinary input, individualized dosimetry, and patient-specific dose reduction were used to ensure t...
Source: Adv Data - June 16, 2023 Category: Epidemiology Authors: Duncan E K Sutherland Raghava Kashyap Price Jackson James P Buteau Declan G Murphy Brian Kelly Lavinia Spain Shahneen Sandhu Arun A Azad Elizabeth Medhurst Grace Kong Michael S Hofman Source Type: research
Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer
Ther Adv Med Oncol. 2023 Jun 6;15:17588359231179309. doi: 10.1177/17588359231179309. eCollection 2023.ABSTRACT[177Lu]Lu-PSMA has recently been approved for use in the post-taxane, post-novel hormonal-agent setting in patients with metastatic castration-resistant prostate cancer. As a beta-emitting radioligand targeting prostate-specific membrane antigen (PSMA), it delivers radiation to cells expressing PSMA on their surface. In pivotal clinical trials, patients were selected for this treatment based on positron emission tomography (PET)/CT imaging, requiring PSMA-avid disease with no evidence of discordant disease on 2-[18...
Source: Adv Data - June 16, 2023 Category: Epidemiology Authors: Louise Kostos James P Buteau Michael S Hofman Arun A Azad Source Type: research
Cheese consumption and multiple health outcomes: an umbrella review and updated meta-analysis of prospective studies
Adv Nutr. 2023 Jun 14:S2161-8313(23)01328-5. doi: 10.1016/j.advnut.2023.06.007. Online ahead of print.ABSTRACTThis umbrella review aims to provide a systematic and comprehensive overview of current evidence from prospective studies on the diverse health effects of cheese consumption. We searched PubMed, Embase, and Cochrane Library to identify meta-analyses/pooled analyses of prospective studies examining the associations between cheese consumption and major health outcomes from inception to August 31, 2022. We reanalyzed and updated previous meta-analyses and performed de novo meta-analyses with recently published prospec...
Source: Adv Data - June 16, 2023 Category: Epidemiology Authors: Mingjie Zhang Xiaocong Dong Zihui Huang Xue Li Yue Zhao Yingyao Wang Huilian Zhu Aiping Fang Edward L Giovannucci Source Type: research
Low-dose acetylsalicylic acid for cancer prevention considering risk factors: A retrospective cohort study
CONCLUSIONS: Our results suggest that aspirin intake is associated with a reduced incidence of colorectal, pancreatic, and prostate cancers and lymphomas.PMID:37302674 | DOI:10.1016/j.annepidem.2023.06.002
Source: Annals of Epidemiology - June 11, 2023 Category: Epidemiology Authors: D ídac Florensa Jordi Mateo Francesc Solsona Leonardo Galv án Miquel Mesas Ramon Pi ñol Leonardo Espinosa-Leal Pere Godoy Source Type: research
